There aren’t many companies that can post their first-ever GAAP profit, blow past a billion dollars in quarterly sales for a flagship drug, and still watch their stock get carved up by a quarter in a single session. That was the strange fate of Alnylam Pharmaceuticals on July 30, when a headline-grabbing earnings report collided with a guidance cut that investors read as a crack in the company’s core growth narrative.
The numbers themselves were hardly the stuff of disaster. Revenue came in at $1.291 billion, with net income of $164.5 million — the first profitable quarter in company history. AMVUTTRA, the TTR franchise’s centerpiece, crossed the billion-dollar quarterly threshold for the first time. But Wall Street had penciled in $1.32 billion, and management’s decision to trim full-year TTR net product revenue guidance to a range of $4.2 billion to $4.5 billion — down from a prior $4.4 billion to $4.7 billion — turned a solid print into a catalyst for panic. The explanation, a “normalization” of demand in the ATTR-CM market as pent-up second-line patient needs get worked through, did little to soften the blow.
The shares fell 28.35% intraday on the news, bottoming out at a 52-week low of €172.15. Since then, a tentative recovery has taken hold: the stock has climbed 14.23% off that trough, closing Wednesday at €196.65 with a 3.53% daily gain. On a seven-day view, the equity is up 9.40%, though it still sits barely 13% above its 52-week floor. Technical indicators tell a mixed story — the relative strength index at 34.2 suggests the selling pressure has largely played out, but the stock remains well below its key moving averages, with a 50-day line at €247.17 that would need to be reclaimed to signal anything resembling a structural turnaround.
A Legal Cloud Gathers Quickly
One of the more striking developments in the week following the earnings release was the speed with which shareholder litigation firms circled. At least five outfits — Schall, Brown & Schwartz; Glancy Prongay Wolke & Rotter; Bragar Eagel & Squire; the Law Offices of Howard G. Smith; Kirby McInerney; and the Law Offices of Frank R. Cruz — announced investigations into potential securities law violations. The focus ranges from the guidance cut itself to allegedly misleading statements about TTR growth dynamics, with at least one firm zeroing in specifically on the “normalization” language. That density of legal activity in such a short window is unusual, and while the investigations may ultimately go nowhere, they add a layer of overhang that could keep institutional buyers cautious.
Analysts Split Down the Middle
The sell-side response has been anything but uniform, reflecting genuine disagreement about what the drawdown means. Raymond James upgraded the stock from “Outperform” to “Strong Buy” on August 3, citing an attractive risk-reward profile in the pipeline despite the share price damage, with a $420 price target. Citigroup affirmed its buy rating the same day but trimmed its target from $380 to $340. Two days earlier, Stifel Nicolaus had slashed its target from $444 to $318, while Wells Fargo cut from $377 to $316 while maintaining an “Equal Weight” stance. The resulting target range — $316 to $420 — is a wide spread that underscores just how much disagreement exists over whether the sell-off was an overreaction or a necessary repricing.
The consensus target sits at €334.45, implying roughly 70.1% upside from Wednesday’s close. That kind of gap between price and analyst expectations is precisely what draws value-oriented investors to the story — and precisely what makes the bears nervous.
Should investors sell immediately? Or is it worth buying Alnylam?
Beyond AMVUTTRA: The Pipeline Carries the Bull Case
What keeps the bullish thesis alive is the breadth of activity outside the TTR franchise. Management highlighted an exclusive agreement with BeOne Medicines to commercialize AMVUTTRA in China, an AI-focused RNAi research collaboration with Inceptive, an expanded partnership with Komodo Health, and a cooperation with a California health system on AI-driven early detection of cardiac amyloidosis. Phase 2 studies are underway for ALN-6400 in von Willebrand disease and for Mivelsiran in Down syndrome-associated Alzheimer’s disease. The June 2026 Inceptive deal was followed by a March 2026 licensing agreement with Tenaya Therapeutics, adding further optionality.
Insider activity has been quiet, with a modest net sell volume of $1.1 million over three months — not a red flag, but hardly a vote of confidence either.
The First-Line Question
For the stock to sustain any recovery, the key metric to watch is whether AMVUTTRA can transition from serving backlogged second-line demand to capturing durable first-line share in the ATTR-CM market. Management reports that new first-line patients now account for the majority of category growth, which would suggest the drug is embedding itself as a foundational therapy despite the reduced guidance. If that trend holds, the “normalization” narrative becomes a one-time reset rather than the beginning of a prolonged deceleration.
If it doesn’t, the bears have a clear path: the ATTR-CM market may simply be harder and slower to grow than originally modeled, and further downward revisions could follow. The €172.15 low would then come back into play, with the stock’s year-to-date loss of 41.97% — and a 46.46% decline over twelve months — potentially widening further. The annualized 30-day volatility of 94.74% leaves little room for complacency.
What Happens Next
The second half of 2026 carries meaningful catalysts. Phase 1 and Phase 2 data for ALN-6400, along with Phase 1 results for ALN-2232, are expected, and both will test whether the pipeline beyond AMVUTTRA has genuine legs. For now, the stock sits in a consolidation zone above its 52-week low, with the 50-day moving average as the first real technical hurdle. A decisive move above that level would open the door toward the consensus target; a failure to hold the recent gains would put the lows squarely back in focus.
What’s clear is that Alnylam now trades as two stories running in parallel: a core business that has crossed into profitability but faces a demand reset, and a pipeline that looks more diversified than it did a year ago. The legal investigations are worth taking seriously, though they likely concern communication quality more than fundamental substance. The shares have stabilized, but “stabilized” is not the same as “recovered” — and the next few months will determine which word applies.
Ad
Alnylam Stock: Buy or Sell?! New Alnylam Analysis from August 6 delivers the answer:
The latest Alnylam figures speak for themselves: Urgent action needed for Alnylam investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 6.
Alnylam: Buy or sell? Read more here...
